Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection

Abstract

This study was designed to evaluate the short-term safety of implanting sustained-release 5-fluorouracil (5-FU) into hepatic cross-section and omentum majus after primary liver cancer resection and its impact on related indexes of liver. Forty patients were selected and divided into an implantation group (n = 20) and a control group (n = 20). On the first day after admission, first week after surgery, and first month after surgery, fasting venous blood was extracted from patients for measuring hematological indexes. The reduction rate of alpha fetoprotein (AFP) on the first week and first month after surgery was calculated, and moreover, drainage volume of the abdominal cavity drainage tube, length of stay after surgery, and wound healing condition were recorded. We found that levels of alanine aminotransferase, aspartate amino transferase, blood urea nitrogen, creatinine, total bilirubin, albumin, and white blood cells measured on the first week and first month after surgery, length of stay, and wound healing of patients in the two groups had no significant difference (P >0.05). Drainage volume and reduction rate of AFP of two groups were significantly different on the first week and first month after surgery (P <0.05). Implanting sustained-release 5-FU into hepatic cross-section and omentum majus after primary liver cancer resection is proved to be safe as it has little impact on related indexes.

Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical Study

“…Chen et al placed fluorouracil implants on the resection margin of the liver, which only caused an increase in the drainage volume. There were no significant differences in liver function and incidence of bleeding and infection as compared with the control group (21). Another concern about late effect of fluorouracil implants is that the drug carrier was made of nonabsorbable material.…”

“…Besides, there was no significant difference in the incidence of side effects as compared with the control group ( 20 ). Intraperitoneal sustained-release implants have also been used to treat liver cancer ( 21 ) and colorectal cancer ( 22 ) with good outcomes. The present study was a multi-center, randomized, open-label, controlled clinical study that focused on the efficacy and safety of intraperitoneal chemotherapy using fluorouracil implants combined with radical resection and postoperative adjuvant chemotherapy for stage III gastric cancer.…”

Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients

“…In China, 5-FU is basically used for chemotherapy of GC, colorectal cancer, breast cancer, and pancreatic cancer. Presently, clinical studies on 5-FU sustained-release preparations have focused on colorectal cancer and liver cancer (Cheng et al, 2013;Yuan et al, 2015;Chen et al, 2016;Li et al, 2018), but rarely on GC. The aim of our study was designed to discuss and evaluate the possibilities of radical surgery combined with 5-FU implants in increasing long-term survival rate.…”

No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer

“…Different from other methods, the use of intraoperative sustained-release 5-FU is promising because of the convenient usage and a long effective time of approximately 1 mo. The use of sustained-release 5-FU implants has shown survival benefits in different types of digestive system tumors such as colon cancer and primary hepatic cellular cancer[ 29 , 30 ]. Furthermore, a few studies on the treatment of gastric cancer, which showed similar results, were also reported by Chinese researchers[ 21 , 22 ].…”